Regeneron and Sanofi announce positive results from phase 2b study of dupilumab in patients with atopic dermatitis

Regeneron Pharmaceuticals, Inc., and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in (more…)

Read More